Funding for this research was provided by:
Academy of Finland
Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimussäätiö
Received: 4 February 2023
Accepted: 6 May 2023
First Online: 31 May 2023
: The study complies with the Declaration of Helsinki. The Ethics Committee of the Hospital District of Southwest Finland approved the study protocol and waived the need for written informed consent for retrospective observational data evaluation.
: Not applicable.
: Dr. Knuuti received consultancy fees from GE Healthcare and AstraZeneca and speaker fees from GE Healthcare, Bayer, Lundbeck, Boehringer-Ingelheim, Pfizer and Merck, outside of the submitted work. Dr. Saraste received consultancy fees from Amgen and Astra Zeneca, Boehringer Ingelheim and Pfizer, and speaker fees from Abbott, Astra Zeneca, and Bayer. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.